Uterine fibroid disease poses complications that far too often disrupt the natural sequence of events in a women’s life: conception through pregnancy and childbirth through to menopause. With the help of Delta Sigma Theta Sorority funding, NCCU will challenge this status quo.
The goals of this proposal are twofold: (1) to further the discovery of a viable treatment modality for uterine fibroids that takes advantage of the material properties of LiquoGel™ and (2) to bring more attention to uterine fibroid disease through community engagement.
These goals will be accomplished through two objectives: (1) to evaluate the effectiveness of LiquoGel™ administered ex-vivo into human uterine fibroid tissue and in-vivo into living mice models and (2) to produce an annual conference to educate the general public about uterine fibroid disease and the available treatment choices. These activities are linked. Any breakthrough discoveries in the treatment of uterine fibroids by means other than surgery must be shared as soon as possible to generate stakeholder interest and support.